2021 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
 

2021 TCT Meetings Policy for Abstracts 
 
ASTCT and CIBMTR extended the deadline to submit your research for The 2021 TCT Meetings Digital Experience. Abstract submissions close on October 23, 2020 at 11:59 p.m. PDT. You can submit your abstracts here.
 
Abstract Eligibility
  • Work submitted for presentation should not have been reported previously in an archival scientific publication, either as an article or as an abstract, at the time of submission.
  • Data that has been, or will be, presented at *any other meeting before being presented at the 2021 TCT Meetings Digital Experience, will not be accepted for presentation.

*Due to the overlap in abstract submission/presentation timelines for the 2020 ASH Annual Meeting, data submitted to/presented at the 2020 ASH Annual Meeting is acceptable for submission to the 2021 TCT Meetings Digital Experience.

Conference Registration Fee

  • Abstract presenting authors will be eligible for a registration discount. If your presentation is accepted, you will receive a code to use when registering that will automatically apply the reduction in your registration rate.

Abstract Submission Fee

  • There is a $50 non-refundable abstract submission fee.

2021 - TCT Meetings - Abstract Categories

Abstract data/research must apply to one of the following 2021 TCT Meetings abstract categories.

  • Acute and chronic leukemia (AML, MDS, MPD, ALL, CML, CLL) – Basic/preclinical
  • HSCT, Gene and Other Cellular Therapies in countries with constrained resources
  • Acute and chronic leukemia (AML, MDS, MPD, ALL, CML, CLL)—Clinical
  • Immune Reconstitution and Immunobiology
  • Acute Regimen-Related Toxicity and Supportive Care
  • Immunotherapy
  • Cellular and Gene Therapy— Basic/preclinical
  • Infectious Diseases and Cytotoxic T-Lymphocytes
  • Cellular and Gene Therapy— Clinical, processing
  • IT and Informatics for Transplant and Cellular Therapy (CIBMTR)
  • Conditioning regimens
  • Late Effects and Quality of Life
  • Donor Health and Safety
  • Lymphoma/Myeloma— Basic/preclinical
  • Graft Sources (Related, matched and mismatched unrelated, haplo, autologous, cord blood, bone marrow and peripheral blood)
  • Lymphoma/Myeloma— Clinical
  • Graft-versus-Host and graft versus tumor - Basic/preclinical
  • Marrow Failure Syndromes (Congenital and Acquired)
  • Graft-versus-Host and graft versus tumor—Clinical: Prevention, treatment and biomarkers)
  • Advanced Practice Professionals (For Advance Practice Provider Track)
  • Health Services and Equity in Transplant and Cellular Therapy
  • Quality and Transplant Program Administration (for Administrative Director Track)
  • Hematopoietic stem cell niche, biology, expansion
  • Study Design and Statistics
  • Hemoglobinopathies, Primary Immune Deficiencies and Inborn Errors and Metabolism—Basic/preclinical
  • Transplant and Cell Therapy for Aged and Geriatric Populations
  • Hemoglobinopathies, Primary Immune Deficiencies and Inborn Errors and Metabolism—Clinical
  • Transplantation Data Management (for Clinical Research Professionals/Data Managers Track)
  • HSCT for Autoimmune Disorders
  • Transplantation Pharmacology (for Pharmacists Track)
 
Responsibility of Abstract Authors
  • The first author listed for each abstract serves as the Presenting Author and is the primary contact for all correspondence regarding the abstract.
  • The Presenting Author is responsible for the following:
    • Ensuring that all authors have read the abstract and agreed to be co-authors.
    • Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by the TCT Meetings.
    • Obtaining all of the conflict-of-interest disclosure information from co-authors.
    • Making certain that abstracts are complete (tables included and labeled) and written in clear, concise and grammatically correct English, so that reviewers are able to focus solely on the scientific merits of the submission. For authors with any questions regarding the clarity, grammar or spelling of their abstract, we encourage identifying and using an independent reviewer to edit the abstract prior to submission.
    • Ensuring that they will be prepared to present and to respond to questions regarding the abstract. If that is not the case, the authors should choose a poster as their preference.
  • Each abstract author agrees and certifies that they:
    • Have read all of the rules and agrees to be bound by them.
    • Are responsible for submission of the abstract in accordance with the rules, and waives any and all claims against ASTCT/CIBMTR/TCT Meetings and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.

Abstract Review

Abstracts are peer reviewed on their scientific merits and according to subject category. Individuals submitting abstracts must indicate the appropriate review category. The ASTCT/CIBMTR/TCT Meetings reserve the right to make minor editorial grammatical/spelling changes if required for clarity of presentation. Abstracts may be re-categorized to a more appropriate category based on guidance from the TCT Meetings Co-Chairs.

Abstract Corrections

All changes/edits to submitted abstracts are strictly the responsibility of the first author and must be conducted within the confines of the abstract submission portal. Requests for assistance in accessing abstracts to allow for modifications, should be submitted in writing to TCTabstracts@astct.org.

Abstract Withdrawals

Abstract withdrawals can be made within the Speaker Center by the first author, no later than October 23, 2020. Abstract withdrawal requests after October 23, 2020 must be made, in writing only to TCTabstracts@astct.org. ASTCT and CIBMTR staff cannot fulfill any withdrawal requests by phone.

Accepted abstracts that remain in the submission system on November 16, 2020 may be published online and in ASTCT’s journal, TCT: Transplantation and Cellular Therapy, as submitted.

Incomplete Abstracts

Any submitted abstract deemed incomplete within the submission system on October 24, 2020 at 12:01 AM PST will be eliminated without further notification prior to abstracts being distributed to the 2021 TCT Meetings Abstract Review Committees.

Late-Breaking Abstracts

The submission of late-breaking abstracts will be allowed from November 16 – December 6, 2020 at 11:59 PM (PT).

Late-breaking abstract authors must complete a request for information to explain the need for submission during the late-breaking abstract submission process, which will be shared with the abstract reviewers and program Co-Chairs.

Accepted late-breaking abstracts will be included in 2021 TCT Meetings app and on the TCT website, but will not be included in the printed TCT Journal Supplement distributed at TCT Meetings.

Embargo

Abstracts submitted for presentation will be embargoed by the author(s) and the 2021 TCT Meetings Digital Experience, upon submission.

The embargo will be lifted and abstracts will be made available for viewing January 11, 2021.

Copyright

Authors assign copyright of the abstract to ASTCT upon submission, unless one of the authors is a U.S. Federal employee. This means that the identical abstract may not be republished or submitted to another meeting; however, Elsevier may grant permission for reuse of abstract content on behalf of ASTCT. You can request to re-use an abstract here.

Conflict of Interest

The ASTCT and CIBMTR are committed to ensuring the integrity of its educational programming along with aiding the professional development of those individuals who are involved in advancing science and improving the diagnosis of and treatment of patients. To that end, the ASTCT and CIBMTR rigorously review the programming offered at its educational sessions to ensure that those sessions that involve commercial content focus on the science and that all participants in ASTCT/CIBMTR educational events involving CME comply with ACCME Standards for Commercial Support. Further, we ask that the focus of educational programming (including abstracts) be educational as opposed to promotional and that to the extent feasible, generic names be utilized in lieu of a commercial product name.

If you have any questions, contact TCTabstracts@astct.org.